Induction Chemotherapy for Locally Advanced Esophageal Cancer

Imagem de Miniatura
Arquivos
art_HARADA_Induction_Chemotherapy_for_Locally_Advanced_Esophageal_Cancer_2020.PDF (441.09 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
Citação
JOURNAL OF GASTROINTESTINAL CANCER, v.51, n.2, p.498-505, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Concurrent chemoradiotherapy followed by surgery is the standard treatment for locally advanced esophageal cancer (EC), and the role of induction chemotherapy (IC) remains unclear. We aimed to study if the addition of IC to standard treatment increases the rate of pathologic complete response (pCR). Methods We assembled a retrospective analysis of patients (pts) diagnosed with locally advanced EC and treated with preoperative chemoradiotherapy followed by esophagectomy (CRT+S), preceded or not by IC, between 2009 and 2017. Patients' characteristics, tumor variables, and treatment outcomes were evaluated. The Kaplan-Meier method was used to estimate overall survival and the Cox proportional hazard model to evaluate prognostic factors. Results One hundred and three patients were studied, with a median age of 62 years (range 37-84). Seventy-five patients (73%) were male, 67 (65%) had squamous cell carcinoma, and 31 (30%) had adenocarcinoma. Forty-three patients (41.7%) received IC followed by CRT+S (IC+CRT+S). The most frequent IC consisted of paclitaxel and platinum chemotherapy (90%), and the median number of cycles was 2. All patients received CRT+S. Concurrent chemotherapy was a combination of paclitaxel and platinum in 94 patients (91%). There was no statistically significant difference in pCR between the IC group and the standard CRT+S group. The pCR was 41.9% and 46.7% in the IC+CRT+S and CRT+S groups (p = 0.628), respectively. In the multivariate analysis, pCR was an independent prognostic factor for time to treatment failure (TTF) (HR 0.35, p = 0.021), but not for overall survival (OS) (p = 0.863). The factor that significantly affected OS in the multivariate analysis was positive lymph node (HR 5.9, 95%, p = 0.026). Conclusions Our data suggest that the addition of IC to standard CRT + S does not increase the pCR rate in locally advanced EC. No difference in OS was observed between pts. that received or not IC. Regardless of the treatment received, pts. achieving a pCR presented improved TTF.
Palavras-chave
Esophageal cancer, Induction chemotherapy, Chemoradiotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/35944
Referências
  1. Ajani JA, 2013, ANN ONCOL, V24, P2844, DOI 10.1093/annonc/mdt339
  2. Al-Batran SE, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4004
  3. Blackham AU, 2015, J SURG ONCOL, V112, P597, DOI 10.1002/jso.24050
  4. Chen DY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08604
  5. Chen GZ, 2017, J THORAC DIS, V9, P849, DOI 10.21037/jtd.2017.03.23
  6. Goodman KA, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4012
  7. Greally M, 2019, J THORAC ONCOL, V14, P540, DOI 10.1016/j.jtho.2018.10.152
  8. Hoeppner J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2564-y
  9. INCA, 2017, EST 2018 CANC INC BR
  10. Jin J, 2004, INT J RADIAT ONCOL, V60, P427, DOI 10.1016/j.ijrobp.2004.03.033
  11. Lin EW, 2016, ONCOGENE, V35, P5337, DOI 10.1038/onc.2016.34
  12. Makino T, 2018, DIS ESOPHAGUS, V31, DOI 10.1093/dote/dox130
  13. Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13
  14. Murphy MB, 2017, CANCER-AM CANCER SOC, V123, P4106, DOI 10.1002/cncr.30953
  15. Noronha Vanita, 2016, J Gastrointest Cancer, V47, P294, DOI 10.1007/s12029-016-9830-8
  16. Peiffert D, 2012, J CLIN ONCOL, V30, P1941, DOI 10.1200/JCO.2011.35.4837
  17. Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014
  18. Rice TW, 2010, ANN SURG ONCOL, V17, P1721, DOI 10.1245/s10434-010-1024-1
  19. Robb WB, 2015, ANN SURG, V261, P902, DOI 10.1097/SLA.0000000000000991
  20. Ruhstaller T, 2018, ANN ONCOL, V29, P1386, DOI 10.1093/annonc/mdy105
  21. Silva S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.5523
  22. Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5
  23. Soror T, 2018, J THORAC DIS, V10, P4069, DOI 10.21037/jtd.2018.06.85
  24. Tsutsumi S, 2017, CANCER SCI, V108, P1119, DOI 10.1111/cas.13237
  25. van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
  26. Zum Buschenfelde CM, 2011, J NUCL MED, V52, P1189, DOI 10.2967/jnumed.110.085803

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/35
Artigos e Materiais de Revistas Científicas - ODS/03